The obtained results allow us to consider newly synthesized daunorubicin derivatives as a basis for the creation of potential antitumor agents with high cytotoxicity towards cancer cells and reduced systemic toxicity in vivo.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1.

Author Contributions: Conceptualization, A.A.K., M.E.N. and V.K.B.; methodology, A.A.K., A.B.T., O.I.A., L.V.A., A.A.G., Z.S.K., M.V.A., E.V.R., V.A.P., V.N.C., Y.R.A. and M.I.S.; software, A.A.G., Z.S.K., M.V.A., E.V.R., V.A.P. V.N.C. and M.I.S.; validation, A.B.T., L.V.A., Z.S.K., E.V.R. and V.A.P., investigation, A.A.K., A.B.T., O.I.A., L.V.A., A.A.G., Z.S.K., M.V.A., E.V.R., V.A.P., Y.R.A. and M.I.S.; resources, A.A.K., A.B.T., N.O.A., M.E.N. and V.K.B.; data curation, A.B.T., V.A.P., Y.R.A. and N.O.A., ; writing—original draft preparation, A.A.K., A.B.T., O.I.A., L.V.A., V.A.P. and Y.R.A.,; writing—review and editing, N.O.A., M.E.N. and V.K.B.; visualization, A.A.K., O.I.A., V.N.C., V.A.P. and M.E.N.,; supervision, M.E.N. and V.K.B.; project administration, N.O.A., M.E.N. and V.K.B.; funding acquisition, A.B.T. and N.O.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Non-Profit Joint-Stock Company "Korkyt Ata Kyzylorda University".

Institutional Review Board Statement: The animal study protocol was approved by the Institutional Ethics Committee of the Federal State Budgetary Institution of Science Federal Research Center for Problems of Chemical Physics and Medical Chemistry of the Russian Academy of Sciences (Approval No. 61date 19.09.2022). All cell lines were purchased from the collection of the Institute of Cytology, Russian Academy of Sciences (St. Petersburg).

Informed Consent Statement: Not applicable.

Acknowledgments: The authors would like to acknowledge the Ministry of Science and Higher Education of the Russian Federation (Contract No. 075-00276-25-00) and the Center for Molecular Composition Studies of INEOS RAS. The biological part of this work was supported by the budget of the IPAC RAS (№ FFSG-2024-0021).

Data Availability Statement: The original contributions presented in this study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author(s).

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Martins-Teixeira, M.B.; Carvalho, I. Antitumour Anthracyclines: Progress and Perspectives. *ChemMedChem* **2020**, *15*, 933–948.
2. Hills, R.K. Evaluating sixty years of UK trials research in acute myeloid leukaemia: Lessons for trial design, past, present and future. *Br. J. Haematol.* **2020**, *188*, 29–35.
3. Schirone, L.; Toldo, S.; Cianflone, E.; Sala, V.; Greco, E. The Role of Anthracyclines in Cardio-Oncology: Oxidative Stress, Inflammation, and Autophagy. *Oxidative Med. Cell Longev.* **2022**, *2022*, 9862524.
4. Bayles, C.E.; Hale, D.E.; Konieczny, A.; Anderson, V.D.; Richardson, C.R.; Brown, K.V.; Nguyen, J.T.; Hecht, J.; Schwartz, N.; Kharel, M.K.; et al. Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology. *Toxicol. Appl. Pharmacol.* **2023**, *459*, 116362.
5. Lima, M.A.C.; Brito, H.R.A.; Mitidieri, G.G.; de Souza, E.P.; Sobral, A.C.G.; Melo, H.; Vasconcelos, G.B.; de Almeida, B.B.D.; Figueiredo, T.A.D.; Filho, M.; et al. Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review. *Int. J. Health Sci.* **2022**, *16*, 39–46.
6. Zhang, J.; Cui, X.; Yan, Y.; Li, M.; Yang, Y.; Wang, J.; Zhang, J. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. *Am. J. Transl. Res.* **2016**, *8*, 2862–2875.
7. Khairnar, S.I.; Kulkarni, Y.A.; Singh, K. Cardiotoxicity linked to anticancer agents and cardioprotective strategy. *Arch. Pharmacal Res.* **2022**, *45*, 704–730.
8. Saharkhiz, S.; Zarepour, A.; Zarrabi, A. A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer. *Int. J. Pharm.* **2023**, *637*, 122845.